Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747673 | 0.85 | TSHR (0.44) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL7649160 | 0.82 | MEN1 (0.46) | TSHRKMT2APDE5ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6747722 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6930340 | 0.78 | TSHR (0.45) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6925571 | 0.78 | ALDH1A1 (0.43) | TSHRKMT2ASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL6926978 | 0.77 | F2 (0.37) | KMT2AALDH1A1 | |
| SCHEMBL6747803 | 0.75 | TSHR (0.47) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6747676 | 0.74 | TSHR (0.44) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7649168 | 0.72 | TSHR (0.46) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6749958 | 0.72 | F2 (0.47) | TSHRKMT2ASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | TSHR 685/4885KMT2A 2438/4885PDE5A 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.